Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Moderna Receives Major Cash Influx
by Lisa M. Jarvis
November 25, 2013
| A version of this story appeared in
Volume 91, Issue 47
Moderna Therapeutics, a privately held, Cambridge, Mass.-based biotech firm focused on developing messenger RNA therapeutics, has scored another $110 million in financing in a round led by its founding investor, Flagship Ventures. Since emerging from stealth mode a year ago, Moderna has managed to attract deep-pocketed investors, even though it has yet to test a drug on humans. In March, AstraZeneca paid $240 million up front for the option to buy into 40 drug candidates developed at Moderna, and in October, the Defense Advanced Research Projects Agency handed the firm $25 million to find mRNA drugs to treat infectious diseases.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter